224 related articles for article (PubMed ID: 33298585)
1. HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells.
Figueroa-Vazquez V; Ko J; Breunig C; Baumann A; Giesen N; Pálfi A; Müller C; Lutz C; Hechler T; Kulke M; Müller-Tidow C; Krämer A; Goldschmidt H; Pahl A; Raab MS
Mol Cancer Ther; 2021 Feb; 20(2):367-378. PubMed ID: 33298585
[TBL] [Abstract][Full Text] [Related]
2. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
Res Sq; 2024 Jan; ():. PubMed ID: 38260385
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Chen R; Rajan S; Overstreet MG; Hurt EM; Thomas SB; Muniz-Medina V; Ward C; Sadowska A; Fleming R; Karanth S; Breen S; Zheng B; Wu Y; Iverson WO; Novick S; O'Day T; Shah DP; Dimasi N; Tiberghien AC; Osbourn J; Walker J
Mol Cancer Ther; 2020 Aug; 19(8):1649-1659. PubMed ID: 32404408
[TBL] [Abstract][Full Text] [Related]
7. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819
[TBL] [Abstract][Full Text] [Related]
8. Amanitins and their development as a payload for antibody-drug conjugates.
Pahl A; Lutz C; Hechler T
Drug Discov Today Technol; 2018 Dec; 30():85-89. PubMed ID: 30553524
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
10. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
11. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
12. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD
Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502
[TBL] [Abstract][Full Text] [Related]
13. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
[TBL] [Abstract][Full Text] [Related]
14. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
15. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
16. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
17. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Tassone P; Goldmacher VS; Neri P; Gozzini A; Shammas MA; Whiteman KR; Hylander-Gans LL; Carrasco DR; Hideshima T; Shringarpure R; Shi J; Allam CK; Wijdenes J; Venuta S; Munshi NC; Anderson KC
Blood; 2004 Dec; 104(12):3688-96. PubMed ID: 15292058
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
Lee HC; Raje NS; Landgren O; Upreti VV; Wang J; Avilion AA; Hu X; Rasmussen E; Ngarmchamnanrith G; Fujii H; Spencer A
Leukemia; 2021 Jan; 35(1):255-258. PubMed ID: 32317775
[No Abstract] [Full Text] [Related]
19. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
20. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
